Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Frontiers in Immunology
|
October 13, 2025
Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors
Andrea Favalli, Giorgio Patelli, Paola Gruarin, et al.
The Oncologist
|
April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.
ESMO Open
|
September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
AIDS Research and Therapy
|
July 6, 2010
Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection
Claudia J Dembek, Sarah Kutscher, Silvia Heltai, et al.
Journal of Translational Medicine
|
December 6, 2014
Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms
Marco Moroni, Silvia Ghezzi, Paolo Baroli, et al.
Clinical Colorectal Cancer
|
September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
Federica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Targeted Oncology
|
July 3, 2017
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
Andrea Sartore-Bianchi, Alessio Amatu, Erica Bonazzina, et al.
Cell Reports. Medicine
|
November 9, 2023
RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
Roberta Angioni, Matteo Bonfanti, Nicolò Caporale, et al.
The Lancet. Oncology
|
April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
ESMO Open
|
August 30, 2017
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
Riccardo Ricotta, Antonella Verrioli, Silvia Ghezzi, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Frontiers in Immunology
|
October 13, 2025
Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors
Andrea Favalli, Giorgio Patelli, Paola Gruarin, et al.
The Oncologist
|
April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.
ESMO Open
|
September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
AIDS Research and Therapy
|
July 6, 2010
Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection
Claudia J Dembek, Sarah Kutscher, Silvia Heltai, et al.
Journal of Translational Medicine
|
December 6, 2014
Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms
Marco Moroni, Silvia Ghezzi, Paolo Baroli, et al.
Clinical Colorectal Cancer
|
September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
Federica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Targeted Oncology
|
July 3, 2017
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
Andrea Sartore-Bianchi, Alessio Amatu, Erica Bonazzina, et al.
Cell Reports. Medicine
|
November 9, 2023
RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
Roberta Angioni, Matteo Bonfanti, Nicolò Caporale, et al.
The Lancet. Oncology
|
April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
ESMO Open
|
August 30, 2017
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
Riccardo Ricotta, Antonella Verrioli, Silvia Ghezzi, et al.
Page
of 7